retatrutide phase New 3 data dropped and everyone's running with the big number. 30% body weight loss at 12mg. Impressive headline. But nobody's talking about 4mg. 📊 19% body weight loss 📊 Retatrutide Side Effects Guide: 21

GLP-1 receptor agonist medications mimic these effects pharmacologically, producing several mechanisms that contribute to weight loss: Reduced appetite and food intake by activating satiety signaling in the brain, these medications meaningfully reduce hunger and food preoccupation for most patients Slower gastric emptying food remains in the stomach longer, prolonging the feeling of fullness after meals Improved insulin sensitivity better glucose regulation reduces post-meal energy crashes that often drive cravings Lower preference for high-calorie foods many patients report shifts in food preferences toward lighter, less calorie-dense options Tirzepatide adds a second mechanism by also activating GIP (glucose-dependent insulinotropic polypeptide) receptors, which is believed to contribute to its greater weight loss effect compared to semaglutide alone

Gut bacteria make short-chain fatty acids (SCFA)

Recognizing that chronic inflammation is a major driver of SLD progression and hepatocarcinogenesis, GLP-1 RAs demonstrate potent anti-inflammatory and tumor-suppressive actions (Que et al., 2019

Paired with clinically appropriate add-ons, it's designed to support a different wellness approach than traditional GLP-1 Weight Loss programs

Retatrutide needs additional TRIUMPH trial results throughout 2026 before submitting for FDA approval in late 2026 or early 2027, with approval expected in late 2027 and launch in early 2028

Heart rate changes observed during treatment have been shown to return to normal once treatment stops